Chart, page-3835

ANP popped up on a scan earlier in the week and had a look to do some personal DD.

Posted it as part of a few scan charts on the STT few days ago.

Quick chart thoughts fwiw at the mo and appears a bit of broker reporting coming on as per qtrly with this from stock head a couple of days ago.

Any BO obviously will need volume support to drive.

https://unauthorised investment advice/health/scopos-powerplays-solid-earnings-on-health-stocks-all-round-but-price-action-stays-with-larger-caps/

Stock of the week

Power’s stock of the week isAntisense Therapeutics (ASX:ANP).

The company has received positive feedback from the Type-C meeting with the US FDA (trial design, dosage, endpoints were all acceptable) on its Phase-2 ATL1102 trial, with the decision on fast designation request expected in August.

ATL1102 is an antisense inhibitor to treat Duchenne Muscular Dystrophy (DMD), a fatal genetic muscle inflammation disorder that affects every 3,500 to 5,000 males worldwide.

“The other area of interest with Antisense is that its long-serving chairman Bob Moses is stepping down to make way for Dr Charmaine Gittleson, a very highly credentialed executive from CSL,” Power said.